BIOA
BioAge Labs, Inc.12.51
+0.05+0.4%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
448.55MP/E (TTM)
0.92Basic EPS (TTM)
13.61Dividend Yield
0%Recent Filings
8-K
BioAge prices $115M offering
BioAge Labs priced an upsized public offering of 5,897,435 common shares at $19.50 each on January 21, 2026, expecting $107.6 million in net proceeds if the underwriters' 30-day option for 884,615 more shares goes unused. Funds will advance BGE-102 trials, NLRP3 and APJ programs, while trimming debt. Closing set for January 23. Customary closing conditions apply.
8-K
BGE-102 eyes DME trial
BioAge Labs expanded oral NLRP3 inhibitor BGE-102 into diabetic macular edema, announcing a Phase 1b/2a proof-of-concept trial starting mid-2026, with data mid-2027. Preclinical DME models showed near-complete vascular leakage protection and 90% microvascular integrity preservation; Phase 1 revealed favorable tolerability and sharp drops in hsCRP, IL-6, IL-1β. Oral dosing targets injection-weary patients. Trials run parallel to CV program.
8-K
BGE-102 slashes hsCRP 86%
BioAge Labs announced positive interim Phase 1 data for BGE-102 on January 12, 2026, showing an 86% median hsCRP reduction at Day 14 in obese participants with elevated inflammation on 120 mg QD, with 93% reaching normalized levels below 2 mg/L. The NLRP3 inhibitor also cut IL-6 by 44% and fibrinogen by 30%, while proving well-tolerated. Full Phase 1 data and Phase 2a initiation are set for 1H 2026. BGE-102 hits hard.
8-K
Positive BGE-102 Phase 1 data
BioAge Labs announced positive interim Phase 1 data for BGE-102 on December 4, 2025. The NLRP3 inhibitor proved well-tolerated across SAD (10-120 mg) and MAD (60-120 mg) cohorts, crushing IL-1β by 90-98% at Day 14 while hitting IC90 CSF levels for brain penetration. BGE-102 supports daily dosing. Phase 2a starts 1H26; early data risks non-replication.
10-Q
Q3 FY2025 results
BioAge Labs posted Q3 collaboration revenue of $2.1M from its Novartis deal, up from zero a year ago, yet R&D expenses dipped 8% y/y to $18.5M as azelaprag costs vanished post-termination while BGE-102 and APJ programs ramped. Operating loss narrowed to $23.1M from $24.8M y/y, narrowed further by $3.0M other income; net loss improved 14% to $20.2M ($0.56/share). Cash burned $53.4M YTD on ops (FCF not disclosed), leaving $296M runway through 2029 despite $3.5M term loan. Novartis pact funds target discovery. Clinical setbacks loom if Phase 1 disappoints.
IPO
Website
Employees
Sector
Industry
BIOE
Bio Essence Corp.
0.05+0.00
CBDL
CBD Life Sciences Inc.
0.00+0.00
GELS
Gelteq Limited
0.96+0.00
IBO
Impact BioMedical, Inc.
0.44-0.02
LXRX
Lexicon Pharmaceuticals, Inc.
1.20-0.03
NAGE
Niagen Bioscience, Inc.
6.34-0.03
PHGE
BiomX Inc.
1.55-0.18
RGC
Regencell Bioscience Holdings L
16.70-0.56
TELO
Telomir Pharmaceuticals, Inc.
1.40-0.02
TERN
Terns Pharmaceuticals, Inc.
42.92-1.09